Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?

Pharmacological Research

Volumn 59, Issue 3, 2009, Pages 202-206

  Gervasoni, Nicola ^a   Aubry, Jean Michel ^b   Gex Fabry, Marianne ^b   Bertschy, Gilles ^b   Bondolfi, Guido ^b  

^a La Métairie Clinic   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Clomipramine; Complete remission; Lithium augmentation; Treatment resistant depression; Triiodothyronine

Indexed keywords

CLOMIPRAMINE; LIOTHYRONINE; LITHIUM; LITHIUM SULFATE; NORCLOMIPRAMINE; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVALUATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; REMISSION; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TRIIODOTHYRONINE;

EID: 59349103100     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.11.005     Document Type: Article

References (40)

1. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
2. Weissman M.M., Bland R.C., Canino G.J., Faravelli C., Greenwald S., Hwu H.G., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
3. Keller M.B., and Boland R.J. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 44 (1998) 348-360
4. Van Londen L., Molenaar R.P., Goekoop J.G., Zwinderman A.H., and Rooijmans H.G. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 28 (1998) 731-735
5. Asberg M., Montgomery S.A., Perris C., Schalling D., and Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl (1978) 5-27
6. Zimmerman M., Posternak M.A., and Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38 (2004) 577-582
7. Carmody T.J., Rush A.J., Bernstein I., Warden D., Brannan S., Burnham D., et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 16 (2006) 601-611
8. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50 (1998) 97-108
9. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25 (1995) 1171-1180
10. Paykel E.S. Achieving gains beyond response. Acta Psychiatr Scand Suppl (2002) 12-17
11. Paykel E.S. Epidemiology of refractory depression. In: Nolen W.A., Zohar J., Roose S.P., and Amsterdam J.D. (Eds). Refractory depression: Current strategies and future directions. (1994), J. Wiley, Chichester 3-18
12. Nierenberg A.A., and Amsterdam J.D. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 51 Suppl (1990) 39-47 [discussion 48-50]
13. Thase M.E., and Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 Suppl 13 (1997) 23-29
14. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53 (2003) 649-659
15. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9 (1999) 83-91
16. Guscott R., and Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 148 (1991) 695-704
17. Fava M., Uebelacker L.A., Alpert J.E., Nierenberg A.A., Pava J.A., and Rosenbaum J.F. Major depressive subtypes and treatment response. Biol Psychiatry 42 (1997) 568-576
18. Shea M.T., Pilkonis P.A., Beckham E., Collins J.F., Elkin I., Sotsky S.M., et al. Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 147 (1990) 711-718
19. Worthington J., Fava M., Agustin C., Alpert J., Nierenberg A.A., Pava J.A., et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics 37 (1996) 518-522
20. Quitkin F.M. The importance of dosage in prescribing antidepressants. Br J Psychiatry 147 (1985) 593-597
21. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157:1-45.
22. Katz M.M., Koslow S.H., Maas J.W., Frazer A., Bowden C.L., Casper R., et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 17 (1987) 297-309
23. Priebe S., and Broker M. Initial response to active drug and placebo predicts outcome of antidepressant treatment. Eur Psychiatry 12 (1997) 28-33
24. Rush A.J., Fava M., Wisniewski S.R., Lavori P.W., Trivedi M.H., Sackeim H.A., et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25 (2004) 119-142
25. Bondolfi G., Aubry J.M., Golaz J., Gex-Fabry M., Gervasoni N., and Bertschy G. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 136 (2006) 78-85
26. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications, 3rd ed. Cambridge: Cambridge University Press; 2008 [fully rev. and expanded].
27. Lifschytz T., Segman R., Shalom G., Lerer B., Gur E., Golzer T., et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 7 (2006) 203-210
28. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20 (1998) 22-33 [quiz 34-57]
29. Fava M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Alpert J.E., McGrath P.J., et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163 (2006) 1161-1172
30. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37 (2004) 243-265
31. Bauer M., and Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19 (1999) 427-434
32. Zullino D., and Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34 (2001) 119-127
33. Carvalho A.F., Cavalcante J.L., Castelo M.S., and Lima M.C. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther 32 (2007) 415-428
34. Hirschfeld R.M., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63 (2002) 826-837
35. Aronson R., Offman H.J., Joffe R.T., and Naylor C.D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53 (1996) 842-848
36. Pigott T.A., Pato M.T., L'Heureux F., Hill J.L., Grover G.N., Bernstein S.E., et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 11 (1991) 242-248
37. Bowden C.L. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 52 (2001) 51-55
38. Kornstein S.G., and Schneider R.K. Clinical features of treatment-resistant depression. J Clin Psychiatry 62 Suppl 16 (2001) 18-25
39. Hatterrer J.A., and Gorman J.M. Thyroid function in refractory depression. In: Roose S.P., and Glassman A.H. (Eds). Treatment strategies for refractory depression (1990), American Psychiatric Press, Washington, DC 171-191
40. Thase M.E., and Howland R.H. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 24 (1994) 232-240